Differentiation syndrome in acute promyelocytic leukemia: pathogenesis and risk factors

Differentiation syndrome is a treatment complication which can occur in acute promyelocytic leukemia (APL) patients treated with all-trans retinoic acid (ATRA) or arsenic trioxide (ATO), which is characterized by enhanced leukocyte transmigration. Several cellular and molecular mechanisms participate in differentiation syndrome development. This review discusses the changes in expression of adhesion molecules induced during ATRA and ATO treatments and their possible implications in the pathogenesis of this potentially fatal complication.

Saved in:
Bibliographic Details
Main Authors: Rego,Eduardo M., Santana-Lemos,Bárbara A. A., Tamarozzi,Mirela B.
Format: Digital revista
Language:English
Published: Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular 2008
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842008000800009
Tags: Add Tag
No Tags, Be the first to tag this record!